Natriuretic Peptide Levels Predict Heart Thickening Risk in Kidney Disease Patients | Research

The takeaway

Elevated cardiac biomarkers including natriuretic peptides were associated with left ventricular and atrial hypertrophy in chronic kidney disease patients, serving as risk markers for heart complications.

Cardiac risk marker
Elevated natriuretic peptides in CKD patients correlate with heart muscle thickening, enabling early detection of dangerous cardiac remodeling

What the researchers found

Cardiac hypertrophic risk markers including natriuretic peptides were associated with left ventricular and left atrial hypertrophy in chronic kidney disease patients.

Why it matters

Heart disease is the leading killer of CKD patients. Natriuretic peptides as early detection markers could identify patients at risk for heart thickening before symptoms appear, enabling earlier intervention.

The numbers in context

253 patients; 51 LV hypertrophy; 126 LA enlargement; 76 both; ANP and BNP elevated; positive correlation with cardiac dimensions

How the study worked

Clinical observational study measuring cardiac biomarkers and echocardiographic parameters of heart structure in chronic kidney disease patients.

Who was studied

Patients with chronic heart valve disease (aortic and/or mitral) showing cardiac hypertrophy

What this study cannot tell us

Observational study — cannot determine causation. Natriuretic peptide levels can be affected by kidney function itself. Cross-sectional design.

How to read the evidence

Moderate evidence: clinical observational study with established cardiac biomarkers in a relevant patient population.

When this study was published

Published 2021. Natriuretic peptide monitoring in CKD continues to be incorporated into clinical guidelines.

The bigger picture

Natriuretic peptides are already used clinically for heart failure diagnosis. Their role as predictive markers in CKD could guide earlier, more aggressive cardiovascular protection in this high-risk population.

Questions still open

Should natriuretic peptide screening be routine in CKD patients?
Can lowering natriuretic peptide levels prevent cardiac hypertrophy?
Which natriuretic peptide cutoff values best predict hypertrophy risk?

Common questions

What are natriuretic peptides?

Natriuretic peptides (BNP, NT-proBNP) are hormones released by the heart when it's under strain. Higher levels indicate the heart is working harder, often due to thickening of the heart muscle or fluid overload — both common in kidney disease.

Should kidney patients get natriuretic peptide tests?

This study supports using natriuretic peptide levels as an early warning for heart problems in CKD. Talk to your nephrologist or cardiologist about whether this simple blood test should be part of your regular monitoring.

Read the original research

Cardiac hypertrophic risk markers of left ventricle and left atrium in chronic heart failure due to aortic and mitral valve disease.

Acta radiologica (Stockholm, Sweden : 1987), 62(5), 603-609

View on PubMed ↗Publisher’s paper ↗

Citation

Jan, Muhammad Ishtiaq; Khan, Riaz Anwar; Khan, Naeem; Mahak, Aisha; Shah, Azhar Ul Haq Ali; Hussain, Syed Tasleem; Kakakhel, Ahaq Ullah; Murtaza, Iram. (2021). Cardiac hypertrophic risk markers of left ventricle and left atrium in chronic heart failure due to aortic and mitral valve disease.. Acta radiologica (Stockholm, Sweden : 1987), 62(5), 603-609. https://doi.org/10.1177/0284185120933530